AI Science Tracker
EN

Clinical Laboratory

1 discovery from 2026

Discoveries

Potential evaluation of SULT1A3 as an early diagnostic marker for nasopharyngeal carcinoma: a study based on serum proteomics screening and ELISA validation.

Source check: Source checked. Not independent scientific confirmation.

Finding: Primary publisher Results and Research Square V1 agree on the serum/plasma proteomics screen, RF-RFE prioritization of SULT1A3 and independent ELISA cohorts. The first report supports SULT1A3 as a candidate NPC marker, not a clinically ready screening test; cohorts are geographically limited.

Technology: Random forest with recursive feature elimination prioritizes protein candidates from 15 early NPC and 15 VCA-IgA-positive control samples.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Random forest with recursive feature elimination prioritizes protein candidates from 15 early NPC and 15 VCA-IgA-positive control samples.
Test and result
ELISA validation reports SULT1A3 AUC .787 in n=80 and AUC .826 and .796 in separate cohorts n=196 and n=150, with sensitivities/specificities around 77–79%; LTA4H/FGL1 weaker.
Limitation / still unknown
Multistage independent ELISA cohorts directly test the candidate; modest discrimination and single-region cohorts require further multicenter validation.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s12885-026-16428-x · https://pubmed.ncbi.nlm.nih.gov/42365246/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.